Last year the labs of Mark Zylka and Ben Philpot at the University of North Carolina at Chapel Hill discovered that a class of drugs called topoisomerase inhibitors reduces the expression of long genes. (sciencedaily.com)
Cancer Center investigators demonstrate that topoisomerase inhibitors induce programmed cell death in leukemia cells. (hopkinsmedicine.org)
Although this class of compounds has shown efficacy in a variety of cancers, interest in developing new topoisomerase I inhibitors, indenoisoquinolines, are currently being evaluated in human patients as agents with improved drug stability and measurable blood levels. (vetmed.ucdavis.edu)